Key points from article :
Taysha Gene Therapies has raised $95 million to take new gene therapies into humans.
After selling AveXis to Novartis for $8.7 billion, CEO and SVP regrouped for a new venture.
Taysha has moved quickly since disclosing the $30 million seed round in April.
Raised $95 million series B round to take its lead asset into the clinic this year.
File a further three INDs by the end of 2021 and build a commercial-scale production plant.
TSHA-101, potential treatment for GM2 gangliosidosis, set to be the first drug to enter clinic.
Delivering the gene therapy to mice via a lumbar puncture may improve symptoms.
Taysha plans to file a flurry of INDs to quickly expand its clinical pipeline.
Taysha has identified Rett syndrome prospect TSHA-102 as the next cab off the rank.
Also, INDs for SLC6A1 haploinsufficiency disorder treatment TSHA-103.
SURF1 deficiency candidate TSHA-104 are set to follow by the end of 2021.
Taysha is focused on taking the gene therapies through the clinic and onto the market.
